| dc.contributor.author | Trapani, Dario | |
| dc.contributor.author | Conforti, Fabio | |
| dc.contributor.author | De Pas, Tommaso | |
| dc.date.accessioned | 2020-05-25T12:50:45Z | |
| dc.date.available | 2020-05-25T12:50:45Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Trapani D, Conforti F, De Pas T. Egfr inhibition in a pretreated sacral chordoma: a rolefor erlotinib? Case report and a brief review of literature. Translational Medicine @ UniSa 2017, 16(5): 30-33. | it_IT |
| dc.identifier.issn | 2239-9747 | it_IT |
| dc.identifier.uri | http://www.translationalmedicine.unisa.it/index | it_IT |
| dc.identifier.uri | http://elea.unisa.it:8080/xmlui/handle/10556/4486 | |
| dc.identifier.uri | http://dx.doi.org/10.14273/unisa-2684 | |
| dc.description.abstract | We describe the case of a 69-year old
male with an EGFR- positive Imatinib refractory
sacral chordoma with synchronous lung metastases,
treated with erlotinib, a first- generation EGFR
inhibitor. After disease progression following firstline Imatinib and a combination therapy with
everolimus plus metformin, we made a challenge
with an EGFR tyrosine kinase inhibitor (EGFR TKI),
erlotinib. Despite a brief clinical benefit, the patient
presented a rapid clinical deterioration leading to
death, after 8 weeks of treatment. | it_IT |
| dc.format.extent | P. 30-33 | it_IT |
| dc.language.iso | en | it_IT |
| dc.source | UniSa. Sistema Bibliotecario di Ateneo | it_IT |
| dc.subject | Chordoma | it_IT |
| dc.subject | Erlotinib | it_IT |
| dc.subject | Imatinib refractory | it_IT |
| dc.subject | Sacral tumor | it_IT |
| dc.title | Egfr inhibition in a pretreated sacral chordoma: a rolefor erlotinib? Case report and a brief review of literature | it_IT |
| dc.type | Article | it_IT |
